Infliximab and Adalimumab Concentrations May Vary Between the Enzyme-Linked Immunosorbent Assay and the Homogeneous Mobility Shift Assay in Patients With Inflammatory Bowel Disease: A Prospective Cross-Sectional Observational Study | Zendy

William T. Clarke | Zendy; Konstantinos Papamichael | Zendy; Niels Vande Casteele | Zendy; Katharine A. Germansky | Zendy; Joseph D. Feuerstein | Zendy; Gil Y. Melmed | Zendy; Corey A. Siegel | Zendy; Peter M. Irving | Zendy; Adam S. Cheifetz | Zendy

Open Access

Infliximab and Adalimumab Concentrations May Vary Between the Enzyme-Linked Immunosorbent Assay and the Homogeneous Mobility Shift Assay in Patients With Inflammatory Bowel Disease: A Prospective Cross-Sectional Observational Study

Author(s) -

William T. Clarke,

Konstantinos Papamichael,

Niels Vande Casteele,

Katharine A. Germansky,

Joseph D. Feuerstein,

Gil Y. Melmed,

Corey A. Siegel,

Peter M. Irving,

Adam S. Cheifetz

Publication year - 2019

Publication title -

inflammatory bowel diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.932

H-Index - 146

eISSN - 1536-4844

pISSN - 1078-0998

DOI - 10.1093/ibd/izz202

Subject(s) - medicine , infliximab , adalimumab , observational study , inflammatory bowel disease , prospective cohort study , homogeneous , gastroenterology , cross sectional study , disease , pathology , physics , thermodynamics

This prospective observational study including consecutive patients with inflammatory bowel disease treated with either infliximab or adalimumab showed that although the correlation between the ELISA and the homogeneous mobility shift assay was good for both drugs, the agreement was poor.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research